Intestinal gene delivery platform enGene nets $13.5 mln in Series B
Montréal-based enGene Inc has raised $13.5 million in Series B financing. The round was backed by an international venture capital syndicate led by Dutch firm Forbion Capital Partners and joined by Québec's Fonds de solidarité FTQ and Russian investor group Pharmstandard International S.A. Existing investor Merck Lumira Biosciences Fund, which is managed by Lumira Capital, also participated in the deal, which brings enGene's total financing to date to over $30 million. The company, which develops novel DNA-based therapeutics, said that it will use the new funds to advance its platform technology for delivering genes to cells lining the gastrointestinal tract.
26 January 2015•6 mins read
